Alopecia areata is a chronic autoimmune disorder ... Which JAK inhibitor(s) demonstrated patients achieving 50% improvement? Which JAK inhibitor(s) demonstrated patients achieving 75% improvement?

inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and ...

Corticosteroids can cause cataracts. As they are used to treat alopecia areata (AA) (at least in adults), all patients with AA, including those with single-patch AA, must be examined by an ...

It is estimated that there are around 300,000 people in the US with severe alopecia that could be eligible for treatment with Olumiant (baricitinib), said the agency. In trials, patients who had ...

Please provide your email address to receive an email when new articles are posted on . Alopecia areata was classified as early-onset, severe or prolonged. Each additional atopic comorbidity ...

Patients want the public to know more about alopecia areata, but at the same time, they want to hide the disease. Nishimura thought what they needed was a spokesperson for them. And who else ...

Olumiant was cleared by the MHRA for severe alopecia in adults in 2022, around a year before the UK regulator backed Litfulo for patients aged 12 and over with the autoimmune disorder, which ...

Alopecia areata causes sudden hair loss and can have a significant negative impact on patients’ quality of life and psychological health. HCW9302 is an injectable, first-in-kind interleukin 2 (IL-2) ...

This is based on the continued emergence of bempikibart data in alopecia areata patients with longer-term follow-up from Part A of the SIGNAL-AA Phase 2a clinical trial, the robust pharmacologic ...